Home>>Signaling Pathways>> Apoptosis>> PD-1/PD-L1 interaction>>BMS-1166 (PD-1/PD-L1-IN1)

BMS-1166 (PD-1/PD-L1-IN1)

Catalog No.GC31753

BMS-1166 (PD-1/PD-L1-IN1) is a potent PD-1/PD-L1 immune checkpoint inhibitor.

Products are for research use only. Not for human use. We do not sell to patients.

BMS-1166 (PD-1/PD-L1-IN1) Chemical Structure

Cas No.: 1818314-88-3

Size Price Stock Qty
10mM (in 1mL DMSO)
$228.00
In stock
5mg
$207.00
In stock
10mg
$342.00
In stock
25mg
$639.00
In stock
50mg
$1,170.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM.

BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with IC50 of 1.4 nM in a homogenous time-resolved fluorescence binding assay[1]. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation. BMS-1166 dose dependently abolishes the inhibition of ECs stimulation by sPD-L1[2].

[1]. Guzik K, et al. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J Med Chem. 2017 Jul 13;60(13):5857-5867. [2]. Skalniak L, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8(42):72167-72181.

Reviews

Review for BMS-1166 (PD-1/PD-L1-IN1)

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BMS-1166 (PD-1/PD-L1-IN1)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.